drugset / Trial / NCT01394939
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of JX-594 (Pexa-Vec) administered intravenously either alone or in combination with Irinotecan in colorectal carcinoma patients who are refractory to or intolerant to standard therapy.
Timeline
- Start
- 2012-01
- Primary completion
- 2015-06
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Subject | Pexastimogene Devacirepvec | Other / unclassified | 3e+08 unknown | Intravenous |
| Subject | Pexastimogene Devacirepvec | Other / unclassified | 1e+09 unknown | Intravenous |